Our work may support the efficacy of systemic steroids as first-line treatment for BWS, but it also highlights that monoclonal antibodies targeting IgE and IL-5, key molecules involved in the pathogenesis of WS, are emerging as effective therapies for relapsing cases. The gene discussed is IGHE; the disease is Beckwith-Wiedemann syndrome.